• Early Data Show TNB-383B to be Safe, Effective for Heavily Treated Myeloma
  • FDA Gives Orphan Drug Status to Potential  Multiple Myeloma Immunotherapy
  • First Patient Dosed in Phase 3 Trial Testing Melflufen Triple Combo
  • PT-112 Shows Promise for Heavily Treated Myeloma Patients
  • MMRF Invests in Indapta’s Natural Killer Cell Therapy to Advance Clinical Trials
  • FDA Approval Sought for Cilta-cel CAR T-cell Therapy
  • FDA Approves Xpovio Triple Combo for Previously Treated Myeloma
  • Bispecific Antibody Shows Early, Promising Responses in Trial
  • CAR T-cell Therapy Cilta-cel Continues to Show Benefits in Heavily Treated Myeloma Patients
  • MMRF Joins Dana-Farber to Advance Research in Smoldering Myeloma
  • Roche’s Cevostamab Leads to Durable, Deep Responses in Heavily Pre-Treated Patients
  • Xpovio Approval Sought for Myeloma Indications in 3 Asian Pacific Markets